Lophora is a clinical-stage CNS drug discovery company developing novel, next generation psychedelic medicines to treat a multitude of psychiatric disorders
www.lophora.com
Founded in 2018 Lophora has successfully finished initial characterization of its lead-candidate LPH-5 through funding granted by the BII (Novo Nordisk Foundation), public funds and experienced biotech investors. Lophora will initiate first-in-human trials by 2024.
Efficacy of LPH-5 has been extensively characterized in vivo and has successfully completed GLP-Tox with expected CTA submission by Q2 2024.
Company Details
- Employees
- 7
- Founded
- -
- Address
- Gyldenlundsvej 21, 01,denmark
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- lophora.com
- Keywords
- Psychiatric disorders, Treatment-Resistant Depression, Major Depression, Central Nervous System.
- HQ
- Gentofte, Capital Region of Denmark
Lophora Questions
Lophora's website is lophora.com
Lophora's LinkedIn profile is https://dk.linkedin.com/company/lophora
Lophora has
7 employees.
View email and phone details for 7
employees at Lophora.
Lophora's industry is
Biotechnology Research
Lophora's top competitors are
Mindmed,
Jupiter Neurosciences, Inc.,
Boost Pharma,
Atai Life Sciences,
Anavex Life Sciences,
Breye Therapeutics Aps,
Dyno Therapeutics,
Kariya Pharmaceuticals,
Cybin Inc,
Gilgamesh Pharmaceuticals.
Lophora's categories are Biotechnology Research
Lophora's founding year is 2018
